Download Files:
Abemaciclib-d8
$680 – $2,400
Products Details
Product Description
– Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
Web ID
– HY-16297AS
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Molecular Formula
– C27H24D8F2N8
References
– [1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13.|[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.|[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
CAS Number
– 2088650-53-5
Molecular Weight
– 514.64
Compound Purity
– 99.57
SMILES
– CC1=NC2=C(C=C(C=C2N1C(C)C)C3=NC(NC4=NC=C(C=C4)CN5C([2H])(C([2H])(N(C([2H])(C5([2H])[2H])[2H])CC)[2H])[2H])=NC=C3F)F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– CDK
Pathway
– Cell Cycle/DNA Damage
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
